Atlas Trials

Immunotherapy With Dinutuximab Beta in Combination With Chemotherapy for the Treatment of Patients With Primary Neuroblastoma Refractory to Standard Therapy and With Relapsed or Progressive Disease

Clinical trial NCT05272371 · RECRUITING

Trial details

NCT number
NCT05272371
Sponsor
Jagiellonian University
Status
RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
High-Risk Neuroblastoma
Start date
2021-12-01
Primary completion
2026-09-30
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.